Grifols, S.A. (GRFS)
USD 7.35
(4.7%)
USD 7.35
(4.7%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 13.46 Billion EUR | 3.0% |
| 2022 | 13.07 Billion EUR | 17.95% |
| 2021 | 11.08 Billion EUR | 29.6% |
| 2020 | 8.55 Billion EUR | -1.63% |
| 2019 | 8.69 Billion EUR | 11.78% |
| 2018 | 7.78 Billion EUR | 6.78% |
| 2017 | 7.28 Billion EUR | 13.82% |
| 2016 | 6.4 Billion EUR | 1.61% |
| 2015 | 6.3 Billion EUR | 8.87% |
| 2014 | 5.78 Billion EUR | 54.98% |
| 2013 | 3.73 Billion EUR | -0.34% |
| 2012 | 3.74 Billion EUR | -9.56% |
| 2011 | 4.14 Billion EUR | 250.61% |
| 2010 | 1.18 Billion EUR | 9.54% |
| 2009 | 1.07 Billion EUR | 54.32% |
| 2008 | 698.96 Million EUR | 25.85% |
| 2007 | 555.4 Million EUR | 1.85% |
| 2006 | 545.32 Million EUR | -28.78% |
| 2005 | 765.73 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 13.83 Billion EUR | 2.69% |
| 2024 Q2 | 13.98 Billion EUR | 0.0% |
| 2023 FY | 13.46 Billion EUR | 3.0% |
| 2023 Q3 | 13.49 Billion EUR | 2.17% |
| 2023 Q2 | 13.2 Billion EUR | 0.25% |
| 2023 Q4 | 13.46 Billion EUR | -0.2% |
| 2023 Q1 | 13.17 Billion USD | 0.76% |
| 2022 FY | 13.07 Billion EUR | 17.95% |
| 2022 Q4 | 13.07 Billion USD | 0.0% |
| 2022 Q1 | - EUR | -100.0% |
| 2022 Q2 | 12.61 Billion EUR | 0.0% |
| 2022 Q3 | 13.07 Billion EUR | 3.62% |
| 2021 Q1 | 8.94 Billion EUR | 4.51% |
| 2021 FY | 11.08 Billion EUR | 29.6% |
| 2021 Q4 | 11.91 Billion USD | 0.0% |
| 2021 Q3 | 11.91 Billion EUR | 28.47% |
| 2021 Q2 | 9.27 Billion EUR | 3.75% |
| 2020 Q3 | 8.53 Billion EUR | -0.21% |
| 2020 FY | 8.55 Billion EUR | -1.63% |
| 2020 Q4 | 8.55 Billion EUR | 0.18% |
| 2020 Q2 | 8.55 Billion EUR | -1.53% |
| 2020 Q1 | 8.68 Billion EUR | -0.08% |
| 2019 Q1 | 8.51 Billion EUR | 9.38% |
| 2019 Q3 | 8.74 Billion EUR | 3.64% |
| 2019 Q4 | 8.69 Billion EUR | -0.55% |
| 2019 FY | 8.69 Billion EUR | 11.78% |
| 2019 Q2 | 8.43 Billion EUR | -0.85% |
| 2018 Q3 | 7.63 Billion EUR | 2.28% |
| 2018 Q1 | 7.16 Billion EUR | -1.66% |
| 2018 FY | 7.78 Billion EUR | 6.78% |
| 2018 Q4 | 7.78 Billion EUR | 1.94% |
| 2018 Q2 | 7.46 Billion EUR | 4.14% |
| 2017 Q4 | 7.28 Billion EUR | -1.83% |
| 2017 Q3 | 7.42 Billion EUR | -1.46% |
| 2017 Q2 | 7.53 Billion EUR | -4.55% |
| 2017 Q1 | 7.89 Billion EUR | 23.27% |
| 2017 FY | 7.28 Billion EUR | 13.82% |
| 2016 Q3 | 6.03 Billion EUR | -1.5% |
| 2016 Q2 | 6.12 Billion EUR | 3.13% |
| 2016 FY | 6.4 Billion EUR | 1.61% |
| 2016 Q4 | 6.4 Billion EUR | 6.07% |
| 2016 Q1 | 5.94 Billion EUR | -5.69% |
| 2015 FY | 6.3 Billion EUR | 8.87% |
| 2015 Q2 | 6.02 Billion EUR | -3.5% |
| 2015 Q1 | 6.23 Billion EUR | 7.83% |
| 2015 Q3 | 5.97 Billion EUR | -0.76% |
| 2015 Q4 | 6.3 Billion EUR | 5.44% |
| 2014 Q4 | 5.78 Billion EUR | 4.02% |
| 2014 FY | 5.78 Billion EUR | 54.98% |
| 2014 Q3 | 5.56 Billion EUR | 10.41% |
| 2014 Q2 | 5.03 Billion EUR | 1.42% |
| 2014 Q1 | 4.96 Billion EUR | 33.05% |
| 2013 Q1 | 3.82 Billion EUR | 2.12% |
| 2013 Q2 | 3.9 Billion EUR | 1.97% |
| 2013 Q3 | 3.74 Billion EUR | -4.09% |
| 2013 Q4 | 3.73 Billion EUR | -0.22% |
| 2013 FY | 3.73 Billion EUR | -0.34% |
| 2012 Q2 | 4.07 Billion EUR | 5.61% |
| 2012 Q4 | 3.74 Billion EUR | -5.94% |
| 2012 Q3 | 3.98 Billion EUR | -2.24% |
| 2012 FY | 3.74 Billion EUR | -9.56% |
| 2012 Q1 | 3.85 Billion EUR | -6.87% |
| 2011 Q3 | 3.88 Billion EUR | 1.5% |
| 2011 Q2 | 3.83 Billion EUR | 0.0% |
| 2011 Q4 | 4.14 Billion EUR | 6.55% |
| 2011 FY | 4.14 Billion EUR | 250.61% |
| 2010 Q4 | 1.18 Billion EUR | 0.0% |
| 2010 FY | 1.18 Billion EUR | 9.54% |
| 2009 FY | 1.07 Billion EUR | 54.32% |
| 2008 FY | 698.96 Million EUR | 25.85% |
| 2007 FY | 555.4 Million EUR | 1.85% |
| 2006 FY | 545.32 Million EUR | -28.78% |
| 2005 FY | 765.73 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Amgen Inc. | 90.92 Billion USD | 85.187% |
| AstraZeneca PLC | 61.95 Billion USD | 78.26% |
| Biogen Inc. | 12.04 Billion USD | -11.813% |
| Gilead Sciences, Inc. | 39.37 Billion USD | 65.795% |
| MIRA Pharmaceuticals, Inc. | 558.09 Thousand USD | -2413168.303% |
| Scilex Holding Company | 274.24 Million USD | -4811.039% |
| Scilex Holding Company | 274.24 Million USD | -4811.039% |